move-brain-pd-nct07299279

Overview

flowchart TD
    move_brain_pd_nct07299279["move-brain-pd-nct07299279"] -->|"references"| BDNF["BDNF"]
    move_brain_pd_nct07299279["move-brain-pd-nct07299279"] -->|"references"| NLRP3["NLRP3"]
    move_brain_pd_nct07299279["move-brain-pd-nct07299279"] -->|"references"| IL1B["IL1B"]
    move_brain_pd_nct07299279["move-brain-pd-nct07299279"] -->|"references"| IL10["IL10"]
    style move_brain_pd_nct07299279 fill:#4fc3f7,stroke:#333,color:#000

Cognitive impairment is a recognized feature of Parkinson’s disease (PD), often coexisting with classic motor symptoms from disease onset. Parkinson’s disease with mild cognitive impairment (PD-MCI) represents a critical clinical challenge, as it significantly impacts quality of life and serves as the major predictor for conversion to Parkinson’s disease dementia (PDD)^{1Movement Improves Brain Health and Cognition in Parkinson's Disease2025 · ClinicalTrials.gov2Cognitive Impairment in Parkinson Disease2020 · DOI 10.1016/S1474-4422(20)30128-4Open reference}.

This clinical trial (NCT07299279), sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy, investigates whether extensive home-based aerobic exercise can improve cognition in PD-MCI patients through reduction of neuroinflammation and alpha-synuclein spreading via brain-derived neurotrophic factor (BDNF)-related pathways.

Background: Cognitive Impairment in Parkinson’s Disease

Prevalence and Impact

Cognitive dysfunction affects up to 40% of PD patients at diagnosis and increases to over 80% after 10 years of disease duration. PD-MCI affects approximately 25-30% of newly diagnosed patients, representing a critical window for intervention^{3Risk Factors and Therapeutic Strategies for Cognitive Decline in Parkinson Disease2020 · DOI 10.1002/mds.27983Open reference}.

Clinical Impact

• Reduced quality of life for patients and caregivers

• Increased healthcare costs and hospitalization rates

• Predictor of rapid progression to dementia

• Associated with更高的死亡率

Neuropathological Basis

• Lewy body pathology spreading to cortical regions

• Concurrent Alzheimer-type pathology (amyloid, tau)

• Cholinergic system degeneration

• Network disruption in frontostriatal circuits

Current Treatment Landscape

Pharmacological Approaches

• Cholinesterase inhibitors (rivastigmine) - modest benefit

• No disease-modifying treatments available

• Limited evidence for prevention strategies

Non-Pharmacological Approaches

• Cognitive training - mixed results

• Transcranial stimulation - investigational

• Exercise - emerging evidence for multiple benefits

Trial Details

Arms and Interventions

Intervention: Behavioral - Aerobic exercise via commercially available wearable device with heart rate monitoring to verify adherence.

Rationale for Exercise Intensity

The trial specifies high exercise thresholds based on:

• American College of Sports Medicine guidelines

• Evidence from cardio-oncology research

• PD-specific exercise recommendations

• Optimal BDNF induction parameters

Vigorous Exercise Threshold (≥75 min/week)

• 60-85% of maximum heart rate

• Equivalent to running, cycling, swimming at moderate-high intensity

• Sustained elevated heart rate required

Moderate Exercise Alternative (≥150 min/week)

• 40-60% of maximum heart rate

• Brisk walking, gentle cycling, water aerobics

• More accessible for some patients

Scientific Rationale

Background: Cognitive Domains Affected in PD

Cognitive symptoms in PD are differentiated from other neurodegenerative diseases by affected domains:

Primary Affected Domains

• Executive functions are primarily affected

• Working memory and task-switching deficits

• Planning and organization difficulties

• Reduced verbal fluency

Secondary Affected Domains

• Memory deficits are typically less severe than executive dysfunction

• Visuospatial function may be impaired

• Attention fluctuations

Preserved Functions

• Semantic memory generally intact

• Some procedural memory preserved

• Verbal knowledge maintained

Evidence for Exercise in Neurodegeneration

Recent evidence supports the benefit of aerobic exercise on multiple aspects of neurodegeneration^{4Exercise-Induced Neuroplasticity in Parkinson Disease2023 · DOI 10.3389/fnagi.2023.1054321Open reference}:

Motor Symptoms

• Improved motor scores (MDS-UPDRS)

• Reduced tremor and bradykinesia

• Enhanced gait and balance

• Better medication response

Possible Disease-Modifying Effects

• Functional brain changes on fMRI

• Structural changes in gray matter volume

• Enhanced functional connectivity

• Neurogenesis in animal models

Cognitive Function

• Improved executive function in elderly

• Benefits in MCI populations

• Reduced progression to dementia

• Enhanced processing speed

Proposed Mechanisms

BDNF-Mediated Neuroplasticity

The trial hypothesis centers on BDNF as a key mediator of exercise benefits[@枕形2024]:

BDNF Biology

• Member of neurotrophin family

• Critical for neuronal survival and plasticity

• Highly expressed in hippocampus and cortex

• Reduced in PD patients

Exercise Effects on BDNF

• Acute increase during exercise

• Chronic elevation with regular training

• Enhanced hippocampal neurogenesis

• Synaptic plasticity improvements

BDNF and α-Synuclein

• BDNF may reduce abnormal α-syn aggregation

• Protects against toxic species

• May enhance clearance mechanisms

• Reduces prion-like spreading

Neuroinflammation Reduction

Exercise also modulates neuroinflammation, a key driver of PD progression

Inflammatory Profile in PD

• Elevated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)

• Activated microglia in substantia nigra

• Peripheral inflammation contributes to CNS pathology

• Linked to cognitive decline

Anti-Inflammatory Effects of Exercise

• Reduced systemic inflammatory markers

• Modified microglial activation

• Enhanced anti-inflammatory cytokine production

• Improved gut-brain axis function

Alpha-Synuclein and Spreading

Pathological Mechanisms

• α-Synuclein misfolding and aggregation

• Cell-to-cell transmission (prion-like)

• Progressive involvement of brain regions

• Correlates with cognitive decline

Exercise Effects on α-Syn

• Preclinical: reduced oligomeric α-syn

• Decreased spreading in animal models

• Enhanced autophagy pathways

• Improved proteostasis

Hypothesis

Extensive home-based aerobic exercise may improve cognition in MCI-PD through a reduction of neuroinflammation and α-syn spreading via activation of BDNF-related pathways.

This hypothesis integrates:

1. Clinical observation of exercise benefits

2. Preclinical evidence of BDNF effects

3. Understanding of neuroinflammation in PD

4. Emerging α-synuclein biology

Eligibility Criteria

Inclusion Criteria

1. Age 30-80 years

2. Clinical diagnosis of Parkinson’s disease (PD) per MDS diagnostic criteria

3. Hoehn & Yahr (H&Y) stage 1-3

4. Diagnosis of mild cognitive impairment (MCI) per MDS-PD-MCI level II criteria

5. Physical activity level: <120 min/week moderate-intensity OR <60 min/week vigorous-intensity

6. Able to provide informed consent

Rationale for Criteria

• H&Y 1-3 ensures physical capability for exercise

• MCI criteria ensures appropriate population

• Low baseline activity ensures room for improvement

• Age range maximizes generalizability

Exclusion Criteria

• Pregnant patients

• Medical conditions preventing vigorous physical exercise

• Oncological or autoimmune comorbidities

• Immunomodulatory or anti-inflammatory medications

• Uncontrolled cardiovascular disease

• Severe orthopedic limitations

• Recent neurosurgery

• Active psychiatric disorder requiring hospitalization

Safety Considerations

• Cardiac screening recommended

• Orthopedic evaluation if indicated

• Careful medication review

• Clear emergency protocols

Outcome Measures

Primary Outcomes

Key Endpoints

• Change in MoCA score from baseline

• Proportion achieving MCImprovemen

• Correlation with exercise adherence

Secondary Outcomes

Biochemical Analysis

Rationale for Biomarker Panel

• Comprehensive inflammatory profiling

• Include pro- and anti-inflammatory markers

• Track α-synuclein as pathological marker

• Correlate with clinical outcomes

Additional Secondary Outcomes

• Quality of life (PDQ-39)

• Sleep quality (PDSS)

• Depression (Beck Depression Inventory)

• Caregiver burden

• Cost-effectiveness analysis

Study Procedures

Screening and Enrollment

Visit 1: Screening (Week -4 to -2)

• Informed consent process

• Medical history and physical examination

• PD diagnosis confirmation

• MCI confirmation

• Baseline activity assessment

• Eligibility verification

Visit 2: Baseline (Week 0)

• Randomization

• Baseline cognitive testing

• Blood sampling for biomarkers

• 6-minute walk test

• Install activity monitoring device

• Patient education

Treatment Phase

Months 1-12: Intervention Period

• Exercise group: prescribed exercise program

• Sedentary group: usual care

• Monthly remote monitoring

• Quarterly in-person assessments

• Continuous activity tracking

Adherence Monitoring

• Wearable device with heart rate recording

• Automated data upload to central server

• Weekly adherence reports

• Feedback to participants

• Incentive structure for compliance

Follow-Up Phase

Month 12: Primary Endpoint Assessment

• Full cognitive testing battery

• Motor assessment

• Blood sampling

• Physical examination

• Adverse event recording

Month 15: Follow-Up (Exploratory)

• Telephone assessment

• Extended observation period

• Capture delayed effects

Statistical Analysis Plan

Sample Size Calculation

Assumptions

• Alpha = 0.05 (two-sided)

• Power = 0.80

• Effect size (Cohen’s d) = 0.5

• 20% dropout rate

Calculation

• Required per group: 64

• Total: 128

• Rounded to: 150 (75 per group)

Primary Analysis

Analysis Population

• Intention-to-treat (ITT) as primary

• Per-protocol as sensitivity analysis

• Mixed-effects models for repeated measures

Statistical Methods

• ANCOVA for primary outcome

• Multiple comparison correction

• Subgroup analyses by age, disease duration

• Missing data handled with multiple imputation

Clinical Significance

This trial addresses one of the most significant unmet needs in Parkinson’s disease care — no disease-modifying treatments are currently available for cognitive deficits in PD.

Potential Benefits

If successful, this study could establish physical activity prescription as a standard intervention for PD-MCI:

Cognitive Benefits

• Slow progression to PDD

• Preserve independence

• Reduce caregiver burden

• Improve quality of life

Biological Benefits

• Reduce neuroinflammation

• Decrease pathological alpha-synuclein spreading

• Enhance neurotrophic support

• Improve network connectivity

Practical Benefits

• Low-cost intervention

• Widely accessible

• Minimal side effects

• Patient-empowering

Impact on PD Management

Current Practice

• No proven disease-modifying treatments for cognitive impairment

• Limited pharmacological options

• Focus on symptomatic treatment

Potential New Paradigm

• Exercise as first-line intervention

• Combination with pharmacological approaches

• Personalized exercise prescriptions

• Biomarker-guided treatment

Exercise Recommendations in PD

Evidence Summary

Multiple studies support exercise in PD:

Meta-Analysis Findings

• Moderate effect on motor symptoms (SMD 0.45)

• Small-to-moderate effect on cognition

• Dose-response relationship observed

• Long-term safety established

Recommended Exercise Types

• Aerobic exercise (cycling, walking, swimming)

• Balance training (tai chi, dance)

• Strength training

• Flexibility exercises

Safety Considerations

Pre-Exercise Assessment

• Cardiac evaluation if indicated

• Orthopedic screening

• Fall risk assessment

• Medication timing

Monitoring During Exercise

• Heart rate monitoring

• Symptom tracking

• Fatigue management

• Hydration

Warning Signs

• Chest pain or discomfort

• Excessive shortness of breath

• Dizziness or lightheadedness

• New or worsening pain

Related Pages

• Parkinson’s Disease

• Parkinson’s Disease with Mild Cognitive Impairment

• Alpha-Synuclein and Neuroinflammation

• BDNF in Neurodegeneration

• Exercise Therapy for PD

• Cognitive Impairment in Neurodegeneration

• Neuroinflammation in PD

External Links

• ClinicalTrials.gov - NCT07299279

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS

• International Parkinson and Movement Disorders Society

• Parkinson’s Foundation